A phase 3 clinical trial evaluated the efficacy and safety of nivolumab alone, nivolumab combined with ipilimumab, and ipilimumab alone in patients with previously untreated metastatic melanoma. The study enrolled 945 patients with unresectable stage III or IV melanoma. Progression-free survival (PFS) was the primary endpoint, with overall survival (OS) being a secondary endpoint. The results showed that the combination of nivolumab and ipilimumab significantly improved PFS compared to ipilimumab alone, with a median PFS of 11.5 months versus 2.9 months for ipilimumab. Nivolumab alone also showed improved PFS compared to ipilimumab, with a median of 6.9 months. In patients with PD-L1-positive tumors, the combination therapy was as effective as nivolumab alone, while in PD-L1-negative patients, the combination was more effective than nivolumab alone. The combination therapy was associated with more severe adverse events, particularly grade 3 or 4 events, compared to monotherapy. The study found that the combination of nivolumab and ipilimumab resulted in significantly longer PFS and higher objective response rates than ipilimumab alone. The results suggest that the combination of PD-1 and CTLA-4 checkpoint inhibitors may be more effective in PD-L1-negative tumors. The study was funded by Bristol-Myers Squibb and was conducted in accordance with ethical and clinical guidelines. The findings support the use of combination therapy in patients with metastatic melanoma, although further research is needed to determine its long-term benefits and safety profile.A phase 3 clinical trial evaluated the efficacy and safety of nivolumab alone, nivolumab combined with ipilimumab, and ipilimumab alone in patients with previously untreated metastatic melanoma. The study enrolled 945 patients with unresectable stage III or IV melanoma. Progression-free survival (PFS) was the primary endpoint, with overall survival (OS) being a secondary endpoint. The results showed that the combination of nivolumab and ipilimumab significantly improved PFS compared to ipilimumab alone, with a median PFS of 11.5 months versus 2.9 months for ipilimumab. Nivolumab alone also showed improved PFS compared to ipilimumab, with a median of 6.9 months. In patients with PD-L1-positive tumors, the combination therapy was as effective as nivolumab alone, while in PD-L1-negative patients, the combination was more effective than nivolumab alone. The combination therapy was associated with more severe adverse events, particularly grade 3 or 4 events, compared to monotherapy. The study found that the combination of nivolumab and ipilimumab resulted in significantly longer PFS and higher objective response rates than ipilimumab alone. The results suggest that the combination of PD-1 and CTLA-4 checkpoint inhibitors may be more effective in PD-L1-negative tumors. The study was funded by Bristol-Myers Squibb and was conducted in accordance with ethical and clinical guidelines. The findings support the use of combination therapy in patients with metastatic melanoma, although further research is needed to determine its long-term benefits and safety profile.